Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 13Pain, Postoperative 10Neoplasms 8Agnosia 8Multiple Myeloma 7Cancer Pain 5Breast Neoplasms 5Lung Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Head and Neck Neoplasms 3Colonic Neoplasms 3Trigger Finger Disorder 2Lymphoma 2Hodgkin Disease 2Hematologic Neoplasms 2Ganglion Cysts 2De Quervain Disease 2Chronic Pain 2Burkitt Lymphoma 2Acute Pain 2Vomiting 1Uterine Cervical Neoplasms 1Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Strabismus 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Renal Insufficiency 1

Interventions

Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Acetaminophen Exposure × Acetaminophen × Clear all
NCT02911961 2021-09-02

APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors

Denver Health and Hospital Authority

Phase 4 Withdrawn

Acetaminophen Exposure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡